Florida-based NovaBone Products, LLC has received a patent for its—as stated in the November 12, 2015 news release—“kit for a minimally invasive delivery of a composition for regenerating bone at or near the site of a bony defect.”
NovaBone Gets USPTO Patent for Bone Regeneration Kit
1 min read Premium comments
Secondary
“This patent is for an effectively designed and highly demanded delivery system that will include the use of porous and non-porous glass, as well as various particle sizes, ” said Greg Pomrink, vice president, Research and Development. “This patent demonstrates NovaBone Products’ expertise in formulating collagen and bioactive glass devices that support surgeon’s needs.”
“We are using innovation, along with an aggressive research and development strategy to create devices that will facilitate surgeries while producing enhanced outcomes, ” said Art Wotiz, president, in the new release. “The new patents protect our technology and provide our company with the platform to continue to explore devices that will benefit the medical community and patients.”
Wotiz told OTW, “This allowance brings the total of new patents for our collagen/bioactive glass platform to five. Taken together, our portfolio broadly protects for use of these composites when the amount of bioactive glass is 80% or greater. The allowance includes our MIS delivery system, the favored product of many surgeons.”
“Our collagen/bioactive glass platform is critically important to NovaBone Products as we now have something for every clinician’s preference. We are already seeing rapid growth of sales, and we expect this momentum to accelerate as we get more hospital approvals.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.